Fusion Pharma Closes $212.5 million initial public offering with support from CFGI

CFGI’s Capital Markets team announced that it assisted Fusion Pharmaceuticals (NASDAQ: FUSN) with an initial public offering of 12,500,000 common shares at $17 per share for gross proceeds of $212.5 million, before deducting underwriting discounts, commissions and offering expenses.

The offering granted underwriters a 30-day option to purchase an additional 1,875,000 common shares at the initial offering price, less underwriting discounts and commissions. The shares began trading on June 26, 2020, and the offering closed on June 30, 2020.

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion developed a Targeted Alpha Therapies, or TAT, platform together with a proprietary Fast-Clear linker technology. This enables a connection between alpha particle emitting isotopes and antibodies, as well as other targeted molecules, to selectively deliver the alpha particle payloads to tumors. Fusion’s lead product candidate, FPI-1434, is currently in a Phase 1 clinical trial as a monotherapy for patients with solid tumors expressing IGF-1R.

The CFGI team was led by April Coleman (Capital Markets) and Ray D’Eon (Capital Markets), with support from Lance Fournier.

Subscribe to Our Newsletter
Share This
Related Posts